FRNRX
Price
$42.82
Change
+$0.30 (+0.71%)
Updated
Jul 13 closing price
Net Assets
487.82M
RYBMX
Price
$83.21
Change
-$1.04 (-1.23%)
Updated
Jul 13 closing price
Net Assets
37.75M
Interact to see
Advertisement

FRNRX vs RYBMX

FRNRX vs RYBMX Comparison Chart in %
View a ticker or compare two or three
VS
FRNRX vs. RYBMX commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FRNRX is a Buy and RYBMX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FRNRX has more cash in the bank: 488M vs. RYBMX (37.8M). FRNRX pays higher dividends than RYBMX: FRNRX (1.47) vs RYBMX (0.62). FRNRX was incepted earlier than RYBMX: FRNRX (31 years) vs RYBMX (22 years). RYBMX (1.69) is less costly to investors than FRNRX (1.01). RYBMX is a more actively managed with annual turnover of: 136.00 vs. FRNRX (19.72). FRNRX initial investment is less costly to investors than RYBMX (5%) vs RYBMX (5%). FRNRX has a lower initial minimum investment than RYBMX: FRNRX (1000) vs RYBMX (2500). FRNRX annual gain was more profitable for investors over the last year : 36.70 vs. RYBMX (12.30). FRNRX return over 5 years is better than : 121.43 vs. RYBMX (15.65).
FRNRXRYBMXFRNRX / RYBMX
Total Expense Ratio1.001.6461%
Annual Report Gross Expense Ratio1.011.6960%
Fund Existence31 years22 years-
Gain YTD16.3975.484299%
Front Load6%5%116%
Min. Initial Investment1000250040%
Min. Initial Investment IRAN/AN/A-
Net Assets488M37.8M1,291%
Annual Yield % from dividends1.470.62239%
Returns for 1 year36.7012.30298%
Returns for 3 years56.9015.51367%
Returns for 5 years121.4315.65776%
Returns for 10 years82.9785.5797%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BGI0.55N/A
-0.04%
Birks Group
LAZ41.10-0.31
-0.75%
Lazard
EME764.90-16.88
-2.16%
EMCOR Group
CRBP9.04-0.64
-6.61%
Corbus Pharmaceuticals Holdings
DSGN13.85-1.33
-8.79%
Design Therapeutics